Antimicrobial central venous catheter study
Abstract:
Objective: To collect real-world data to demonstrate the safety and performance of Arrowg+ard Blue® /Arrowg+ard Blue Plus® (AGB/AGB+) central venous catheters (CVCs).
Methods: This observational, retrospective study involved patients who required AGB/AGB+ CVCs at designated general hospitals in USA (22), UK (19) and Germany (2). Data were extracted from electronic medical records. There were no specific inclusion/exclusion criteria. Primary endpoint was successful treatment without an adverse event (AE). Secondary endpoint was rate of AEs.
Results: In total, 384 cases were included from 43 centres and most patients (74%) were >35 years of age. A success rate of 99%, and an overall AE rate of 0.8% were observed. Moreover, the overall infection rate was lower than typically reported for standard catheters. In addition, power injection of contrast media was successful in all 51 cases.
Conclusions: This study indicates the AGB/AGB+ CVCs perform as intended with a high success rate and few AEs. Further large-scale, controlled studies are required to confirm our findings.
Reference:
Philbeck TE, Bardin A, McDonald JG. Observational, retrospective real-world evidence study demonstrates safety, performance and usefulness of antimicrobial central venous catheters. J Int Med Res. 2024 Sep;52(9):3000605241279236. doi: 10.1177/03000605241279236. PMID: 39308254.